Cargando...

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Main Authors: Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2018
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6154848/
https://ncbi.nlm.nih.gov/pubmed/30024813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472189
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!